Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatectomy | 18 | 2013 | 358 | 1.870 |
Why?
|
| Nephrectomy | 11 | 2012 | 179 | 1.600 |
Why?
|
| Prostatic Neoplasms | 18 | 2013 | 1577 | 1.560 |
Why?
|
| Kidney Neoplasms | 12 | 2020 | 450 | 1.300 |
Why?
|
| Prostate-Specific Antigen | 12 | 2013 | 271 | 1.250 |
Why?
|
| Lymph Node Excision | 9 | 2015 | 174 | 1.230 |
Why?
|
| Urinary Bladder Neoplasms | 16 | 2021 | 541 | 1.160 |
Why?
|
| Prostate | 7 | 2018 | 437 | 1.040 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2019 | 186 | 0.900 |
Why?
|
| Laparoscopy | 9 | 2012 | 523 | 0.710 |
Why?
|
| Lymph Nodes | 3 | 2012 | 389 | 0.680 |
Why?
|
| Cystectomy | 10 | 2018 | 165 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 1304 | 0.510 |
Why?
|
| Nomograms | 2 | 2015 | 38 | 0.460 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2012 | 241 | 0.450 |
Why?
|
| Lymphatic Metastasis | 9 | 2015 | 444 | 0.410 |
Why?
|
| Urothelium | 6 | 2021 | 60 | 0.370 |
Why?
|
| Carcinoma | 3 | 2021 | 300 | 0.350 |
Why?
|
| Middle Aged | 40 | 2021 | 29007 | 0.350 |
Why?
|
| Ureteral Neoplasms | 4 | 2019 | 27 | 0.340 |
Why?
|
| Mitomycin | 2 | 2021 | 53 | 0.340 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2010 | 41 | 0.340 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2021 | 128 | 0.320 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 234 | 0.320 |
Why?
|
| Warm Ischemia | 2 | 2012 | 26 | 0.320 |
Why?
|
| Drainage | 1 | 2011 | 262 | 0.310 |
Why?
|
| Biomarkers, Tumor | 8 | 2016 | 1679 | 0.300 |
Why?
|
| Postoperative Care | 1 | 2011 | 312 | 0.300 |
Why?
|
| Ileostomy | 1 | 2009 | 32 | 0.300 |
Why?
|
| Aged | 35 | 2021 | 21456 | 0.290 |
Why?
|
| Granular Cell Tumor | 1 | 2008 | 3 | 0.290 |
Why?
|
| Genital Neoplasms, Male | 1 | 2008 | 12 | 0.290 |
Why?
|
| Scrotum | 1 | 2008 | 28 | 0.280 |
Why?
|
| Neoplasm Staging | 11 | 2018 | 1363 | 0.280 |
Why?
|
| Suture Techniques | 1 | 2009 | 189 | 0.270 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 311 | 0.270 |
Why?
|
| Predictive Value of Tests | 10 | 2015 | 2313 | 0.270 |
Why?
|
| Male | 47 | 2021 | 64979 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 2 | 2010 | 573 | 0.250 |
Why?
|
| Urologic Neoplasms | 3 | 2011 | 38 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 8 | 2018 | 665 | 0.240 |
Why?
|
| Robotics | 4 | 2012 | 108 | 0.230 |
Why?
|
| Ureter | 3 | 2010 | 99 | 0.220 |
Why?
|
| Carcinoma in Situ | 2 | 2018 | 74 | 0.220 |
Why?
|
| Humans | 55 | 2021 | 132201 | 0.210 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 302 | 0.200 |
Why?
|
| Biopsy | 6 | 2014 | 1287 | 0.190 |
Why?
|
| Prognosis | 11 | 2018 | 5015 | 0.180 |
Why?
|
| Cisplatin | 2 | 2015 | 282 | 0.180 |
Why?
|
| Retrospective Studies | 20 | 2016 | 17391 | 0.170 |
Why?
|
| Nephroureterectomy | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 211 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 400 | 0.160 |
Why?
|
| Drug Carriers | 1 | 2020 | 119 | 0.160 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 7123 | 0.150 |
Why?
|
| Erectile Dysfunction | 2 | 2015 | 211 | 0.150 |
Why?
|
| Patient Selection | 4 | 2011 | 731 | 0.150 |
Why?
|
| Hypogonadism | 2 | 2013 | 320 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 1128 | 0.140 |
Why?
|
| Testosterone | 2 | 2013 | 611 | 0.130 |
Why?
|
| Adult | 16 | 2020 | 31600 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2016 | 121 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2019 | 956 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 237 | 0.120 |
Why?
|
| Postoperative Complications | 5 | 2011 | 3139 | 0.120 |
Why?
|
| Vinblastine | 1 | 2015 | 57 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 46 | 0.110 |
Why?
|
| Pelvis | 2 | 2012 | 74 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1829 | 0.110 |
Why?
|
| Electrosurgery | 1 | 2014 | 17 | 0.110 |
Why?
|
| Electrocoagulation | 1 | 2014 | 32 | 0.110 |
Why?
|
| Ureteroscopy | 2 | 2011 | 20 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 64 | 0.110 |
Why?
|
| Female | 23 | 2021 | 70754 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2015 | 303 | 0.100 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 1461 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 2138 | 0.100 |
Why?
|
| Time Factors | 6 | 2020 | 6452 | 0.100 |
Why?
|
| Methotrexate | 1 | 2015 | 350 | 0.100 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 99 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2020 | 13028 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1348 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2019 | 6569 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1444 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2014 | 368 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 689 | 0.090 |
Why?
|
| ROC Curve | 2 | 2011 | 600 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2012 | 95 | 0.090 |
Why?
|
| Muscle Neoplasms | 1 | 2011 | 21 | 0.090 |
Why?
|
| New York City | 1 | 2011 | 65 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 5410 | 0.090 |
Why?
|
| Risk Factors | 8 | 2015 | 10944 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 66 | 0.080 |
Why?
|
| Kidney Pelvis | 1 | 2010 | 47 | 0.080 |
Why?
|
| Hydrogels | 2 | 2021 | 108 | 0.080 |
Why?
|
| Research Design | 1 | 2014 | 743 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 3015 | 0.080 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2009 | 41 | 0.080 |
Why?
|
| Watchful Waiting | 1 | 2009 | 77 | 0.070 |
Why?
|
| Mass Screening | 1 | 2015 | 830 | 0.070 |
Why?
|
| Abdominal Wall | 1 | 2009 | 26 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 134 | 0.070 |
Why?
|
| Urinary Retention | 1 | 2008 | 19 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2009 | 79 | 0.070 |
Why?
|
| Urinary Incontinence | 1 | 2008 | 78 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 258 | 0.070 |
Why?
|
| Diverticulum | 1 | 2008 | 30 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2009 | 334 | 0.070 |
Why?
|
| Brazil | 1 | 2008 | 140 | 0.070 |
Why?
|
| Schwann Cells | 1 | 2008 | 66 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2015 | 1574 | 0.070 |
Why?
|
| Disease Progression | 4 | 2018 | 2230 | 0.070 |
Why?
|
| Urethra | 2 | 2018 | 89 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 436 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2008 | 244 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2009 | 258 | 0.060 |
Why?
|
| BCG Vaccine | 2 | 2018 | 112 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1964 | 0.050 |
Why?
|
| United States | 3 | 2020 | 11675 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2165 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2087 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1295 | 0.050 |
Why?
|
| Survival Rate | 3 | 2011 | 2196 | 0.040 |
Why?
|
| Israel | 1 | 2020 | 48 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2020 | 42 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2011 | 3736 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1714 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3844 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 714 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 33 | 0.040 |
Why?
|
| Probability | 2 | 2009 | 322 | 0.040 |
Why?
|
| Cystoscopy | 1 | 2018 | 46 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 749 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 1008 | 0.030 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 5 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 392 | 0.030 |
Why?
|
| Recurrence | 2 | 2010 | 1453 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2009 | 5173 | 0.030 |
Why?
|
| Incidence | 2 | 2015 | 3377 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 396 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1045 | 0.030 |
Why?
|
| Age Factors | 2 | 2009 | 2920 | 0.020 |
Why?
|
| Hematocrit | 1 | 2013 | 111 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 576 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 3091 | 0.020 |
Why?
|
| Keratins | 1 | 2012 | 52 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 322 | 0.020 |
Why?
|
| Lipids | 1 | 2015 | 561 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 92 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2012 | 159 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2679 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 77 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 373 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 1591 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 472 | 0.020 |
Why?
|
| Adolescent | 1 | 2008 | 20557 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2011 | 200 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2010 | 133 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 1402 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 116 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 60 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2009 | 83 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2009 | 40 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 27 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 248 | 0.020 |
Why?
|
| Penile Erection | 1 | 2008 | 86 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2008 | 3995 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3632 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 2663 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 212 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 414 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 437 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 416 | 0.020 |
Why?
|
| Child | 1 | 2008 | 25783 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 724 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 587 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 796 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1250 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2008 | 255 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 313 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 463 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1354 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2008 | 1255 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1841 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 3402 | 0.010 |
Why?
|
| Acute Disease | 1 | 2008 | 1163 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 766 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 2062 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 9965 | 0.010 |
Why?
|